Matriptase is involved in ErbB-2-induced prostate cancer cell invasion

American Journal of Pathology

Volumn 177, Issue 6, 2010, Pages 3145-3158

  Wu, Shang Ru ^a   Cheng, Tai Shan ^a   Chen, Wen Chi ^b   Shyu, Hsin Yi ^a   Ko, Chun Jung ^a   Huang, Hsiang Po ^c   Teng, Chen Hsin ^a   Lin, Chia Hau ^a   Johnson, Michael D ^d   Lin, Chen Yong ^e   Lee, Ming Shyue ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MATRIPTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

EID: 78650207591     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100228     Document Type: Article

References (88)

1. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW: Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 2002, 32 Suppl:S66-S81
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66
3. Sporn MB: The war on cancer. Lancet 1996, 347:1377-1381
4. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993, 9:541-573 (Pubitemid 2021155)
5. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, Nogue M, Domenech M, Fabregat X: Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 2004, 10:4742-4745
6. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C: HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001, 7:2643-2647
7. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ: Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001, 166:1514-1519
8. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000, 92:1918-1925
9. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L: Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005, 113:619-628 (Pubitemid 40038739)
10. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW Jr, Yu D, Mooney EE, McCrea PD: C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 2000, 19:4864-4875
11. Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB: HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008, 32:307-316
12. Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL: ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 2000, 148:385-397
13. Dawson JP, Bu Z, Lemmon MA: Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 2007, 15:942-954
14. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003, 11:495-505 (Pubitemid 36293841)
15. Lemmon MA: Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009, 315:638-648
16. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167
17. Riese DJ, 2nd, Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20:41-48
18. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137
19. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el N: Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004, 6:846-853
20. Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516
21. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354
22. Montironi R, Mazzucchelli R, Barbisan F, Stramazzotti D, Santinelli A, Scarpelli M, Lopez Beltran A: HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 2006, 37:1137-1144
23. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC: HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000, 60:6841-6845 (Pubitemid 32059149)
24. Scher HI: HER2 in prostate cancer: a viable target or innocent bystander? J Natl Cancer Inst 2000, 92:1866-1868
25. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM: Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004, 90:449-454
26. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442
27. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 2003, 22:237-258
28. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR: Cancer invasion and tissue remodeling: cooperation of protease systems and cell types. Apmis 1999, 107:120-127
29. Johnsen M, Lund LR, Romer J, Almholt K, Dano K: Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998, 10:667-671 (Pubitemid 28477027)
30. Kohn EC, Liotta LA: Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995, 55:1856-1862
31. Chen WT: Proteases associated with invadopodia, and their role in degradation of extracellular matrix. Enzyme Protein 1996, 49:59-71
32. Lin CY, Wang JK, Torri J, Dou L, Sang QA, Dickson RB: Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells: monoclonal antibody production, isolation, and localization. J Biol Chem 1997, 272:9147-9152
33. Cao J, Cai X, Zheng L, Geng L, Shi Z, Pao CC, Zheng S: Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening. J Cancer Res Clin Oncol 1997, 123:447-451
34. Kim MG, Chen C, Lyu MS, Cho EG, Park D, Kozak C, Schwartz RH: Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999, 49:420-428
35. Takeuchi T, Shuman MA, Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999, 96:11054-11061 (Pubitemid 29487326)
36. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ: Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001, 22:104-114
37. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY: Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001, 158:1301-1311
38. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T, Pecorelli S: The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 2003, 98:1898-1904
39. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826
40. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 2006, 15:217-227
41. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH: Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005, 19:1934-1950
42. Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K: In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005, 27:1061-1070
43. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003, 63:1101-1105
44. Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 2004, 279:14899-14908
45. Lee SL, Dickson RB, Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000, 275:36720-36725
46. Meng TC, Lee MS, Lin MF: Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000, 19:2664-2677
47. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF: ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003, 22:781-796
48. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY: The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003, 278:26773-26779
49. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47:3239-3245 (Pubitemid 17082655)
50. Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ, Tilley WD: Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008, 68:830-838
51. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002, 50:222-235
52. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF: Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998, 273:5939-5947
53. Lee MS, Tseng IC, Wang Y, Kiyomiya K, Johnson MD, Dickson RB, Lin CY: Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. Am J Physiol Cell Physiol 2007, 293:C95-C105
54. Lin CY, Tseng IC, Chou FP, Su SF, Chen YW, Johnson MD, Dickson RB: Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front Biosci 2008, 13:621-635
55. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH: Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006, 18:2262-2271
56. Stambolic V, Woodgett JR: Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol 2006, 16:461-466
57. Estrada AC, Syrovets T, Pitterle K, Lunov O, Buchele B, Schimana-Pfeifer J, Schmidt T, Morad SA, Simmet T: Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 2010, 77:378-387
58. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson AM, Saad F: Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 2006, 94:1906-1912
59. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M: Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993, 150:126-131
60. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE: Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994, 86:1140-1145 (Pubitemid 2128729)
61. Gu K, Mes-Masson AM, Gauthier J, Saad F: Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 1996, 99:185-189
62. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN: c-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990, 65:88-92
63. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, Visakorpi T: Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002, 160:339-345
64. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993, 150:1427-1433
65. Mark HF, Feldman D, Das S, Kye H, Mark S, Sun CL, Samy M: Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999, 66:170-178 (Pubitemid 29347506)
66. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP: Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999, 59:803-806
67. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002, 8:1101-1107
68. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001, 6:393-406 (Pubitemid 33818537)
69. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, Honda N, Nakagawa A, Saga S, Hara K: Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006, 68:110-115
70. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5:280-285
71. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K: Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996, 12:2535-2547
72. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ: ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997, 15:2705-2716
73. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R: Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997, 3:21-30
74. Tal-Or P, Di-Segni A, Lupowitz Z, Pinkas-Kramarski R: Neuregulin promotes autophagic cell death of prostate cancer cells. Prostate 2003, 55:147-157 (Pubitemid 36444002)
75. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T: A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 2001, 287:995-1002
76. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, Dickson RB, Kitamura H, Miyazaki K: Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 2006, 97:1327-1334
77. Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E: Gefitinib ('IRESSA'. ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 2004, 130:604-614
78. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS, Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 2001, 15:1953-1962
79. Zhang D, Brodt P: Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003, 22:974-982
80. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000, 275:26333-26342
81. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, DeVere White RW: Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004, 60:257-271
82. Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995, 80:225-236
83. Weigel NL, Moore NL: Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl Recept Signal 2007, 5:e005
84. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S: Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 2004, 4:1633-1649 (Pubitemid 38738322)
85. Basu S, Totty NF, Irwin MS, Sudol M, Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003, 11:11-23
86. Hoyal CR, Gutierrez A, Young BM, Catz SD, Lin JH, Tsichlis PN, Babior BM: Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci USA 2003, 100:5130-5135
87. Johnson JL, Pacquelet S, Lane WS, Eam B, Catz SD: Akt regulates the subcellular localization of the Rab27a-binding protein JFC1 by phosphorylation. Traffic 2005, 6:667-681
88. Lee MS, Kiyomiya K, Benaud C, Dickson RB, Lin CY: Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. Am J Physiol Cell Physiol 2005, 288:C932-C941